11 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
an official letter with the FDA’s questions within 30 days. Verve plans to provide updates pending engagement with the FDA and intends to work closely
S-1
EX-10.3
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S
DRS
EX-10.3
VERV
Verve Therapeutics Inc
16 Apr 21
Draft registration statement
12:00am
OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S
S-1
EX-10.17
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
out of or relating to this Agreement or its engagement pursuant hereto.
(h) The term “Proceeding” shall include any threatened, pending or completed
DEF 14A
7i3fxz5
29 Apr 22
Definitive proxy
7:01am
10-K
v2y3idm
14 Mar 22
Annual report
7:04am
- Prev
- 1
- Next